![](/images/graphics-bg.png)
CD133 Is Associated with Increased Melanoma Cell Survival after Multikinase Inhibition
المؤلفون المشاركون
Simbulan-Rosenthal, Cynthia M.
Gaur, Anirudh
Zhou, Hengbo
AbdusSamad, Maryam
Qin, Qing
Dougherty, Ryan
Aljehane, Leala
Kuo, Li-Wei
Vakili, Sahar
Karna, Kumari
Clark, Havens
McCarron, Edward
Rosenthal, Dean S.
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-19، 19ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-07-16
دولة النشر
مصر
عدد الصفحات
19
التخصصات الرئيسية
الملخص EN
FDA-approved kinase inhibitors are now used for melanoma, including combinations of the MEK inhibitor trametinib, and BRAF inhibitor dabrafenib for BRAFV600 mutations.
NRAS-mutated cell lines are also sensitive to MEK inhibition in vitro, and NRAS-mutated tumors have also shown partial response to MEK inhibitors.
However, melanoma still has high recurrence rates due to subpopulations, sometimes described as “melanoma initiating cells,” resistant to treatment.
Since CD133 is a putative cancer stem cell marker for different cancers, associated with decreased survival, we examined resistance of patient-derived CD133(+) and CD133(-) melanoma cells to MAPK inhibitors.
Human melanoma cells were exposed to increasing concentrations of trametinib and/or dabrafenib, either before or after separation into CD133(+) and CD133(-) subpopulations.
In parental CD133-mixed lines, the percentages of CD133(+) cells increased significantly (p<0.05) after high-dose drug treatment.
Presorted CD133(+) cells also exhibited significantly greater (p<0.05) IC50s for single and combination MAPKI treatment.
siRNA knockdown revealed a causal relationship between CD133 and drug resistance.
Microarray and qRT-PCR analyses revealed that ten of 18 ABC transporter genes were significantly (P<0.05) upregulated in the CD133(+) subpopulation, while inhibition of ABC activity increased sensitivity, suggesting a mechanism for increased drug resistance of CD133(+) cells.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Simbulan-Rosenthal, Cynthia M.& Gaur, Anirudh& Zhou, Hengbo& AbdusSamad, Maryam& Qin, Qing& Dougherty, Ryan…[et al.]. 2019. CD133 Is Associated with Increased Melanoma Cell Survival after Multikinase Inhibition. Journal of Oncology،Vol. 2019, no. 2019, pp.1-19.
https://search.emarefa.net/detail/BIM-1184449
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Simbulan-Rosenthal, Cynthia M.…[et al.]. CD133 Is Associated with Increased Melanoma Cell Survival after Multikinase Inhibition. Journal of Oncology No. 2019 (2019), pp.1-19.
https://search.emarefa.net/detail/BIM-1184449
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Simbulan-Rosenthal, Cynthia M.& Gaur, Anirudh& Zhou, Hengbo& AbdusSamad, Maryam& Qin, Qing& Dougherty, Ryan…[et al.]. CD133 Is Associated with Increased Melanoma Cell Survival after Multikinase Inhibition. Journal of Oncology. 2019. Vol. 2019, no. 2019, pp.1-19.
https://search.emarefa.net/detail/BIM-1184449
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1184449
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)